相关实验视频

Updated: May 2, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

针对复发性或耐火性多发性髓瘤的德基利斯塔马布的有效性和安全性:系统性审查和元分析

Wenze Li¹, Defeng Zhao², Yu Jiao¹

¹Department of Hematology, The First Affiliated Hospital of China Medical University, Shenyang, China.

Frontiers in immunology

|May 12, 2025

概括

在复发性/耐药性多发性髓瘤 (RRMM) 患者中,德克利斯塔马布显示改善了整体生存期. 这种双特异性抗体提供了一个有前途的治疗选择,特别是在组合疗法中,具有可控的副作用.

科学领域:

血液学血液学血液学
在瘤学瘤学.
免疫治疗是一种免疫疗法.

背景情况:

多发性骨髓瘤 (MM) 是一种血液癌症,对于复发性/耐药性患者 (RRMM) 的选择有限.
针对BCMA和CD3的双特异抗体Teclistamab在治疗RRMM方面显示出潜在的潜力.

研究的目的:

评估teclistamab在RRMM患者中的疗效和安全性.
为了比较teclistamab与RRMM的现有治疗方法.

主要方法:

34项涉及4064名患者的研究的系统审查和元分析.
搜索了数据库,包括PubMed,科学网络,EMBASE,科克兰图书馆和临床试验.gov.gov.
评估结果包括整体存活率,反应率和不良事件.

主要成果:

与现有的RRMM治疗相比,德克利斯塔马布的整体存活率更高 (HR=0.69).
现实世界的研究显示了可比的整体反应率 (62%),但生存结果略低.
组合疗法显著改善了整体反应率 (85%与62%相比).

结论:

德克利斯塔马布是RRMM的有效治疗方法,包括以前使用BCMA疗法治疗的患者.
它为克服耐药性和改善早期疾病控制提供了希望.
需要对不同种群进行进一步的研究,特别是亚洲人群.

关键词:

两种特异性的抗体.这是一个元分析.复发性或耐火性多发性骨髓瘤系统性审查系统性审查德克里斯塔马巴巴是什么意思

更多相关视频

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

相关概念视频

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.